(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Toddler given just 3 years to live after strange symptoms makes full recovery - 2Most loved Occasion Dish: What Makes Your Merry Table?
- 3'War is not over': Detailed diagrams of prisons found in cells of Oct. 7 terrorists
- 4Finding Your Motivation: Moves toward a Satisfying Life
- 5Washington resident is infected with a different type of bird flu
- Historical mysteries solved by science in 2025
- RFK Jr. says fewer flu shots for kids may be 'better.' What experts say.
- Vote in favor of Your #1 4\u00d74 SUVs
- Vote In favor of Your Number one Sort Of Blossoms
- Which Exhibition hall Do You Suggest? Vote
- These 3 Nail-Free Finds Completely Transformed My Drab Bathroom
- How to get rid of your Christmas tree — and the 1 thing to never, ever do with it
- From School Dropout to Example of overcoming adversity: My Excursion
- Brilliant and Gleaming: Excellence and Skincare Practices
